GENERLAC

Post-LOE

lactulose

ANDAORAL, RECTALSOLUTION
Approved
Oct 1996
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
6

Mechanism of Action

Osmotic Activity

Pharmacologic Class:

Osmotic Laxative

Clinical Trials (5)

NCT03666546Phase 4Completed

Blood Glucose Response After Oral Intake of Lactulose in Mildly Constipated Patients With Diabetes Mellitus Type 2

Started Nov 2018
24 enrolled
Diabetes Mellitus, Type 2
NCT03515044Phase 2Completed

Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

Started Sep 2018
71 enrolled
Overt Hepatic Encephalopathy
NCT02968498N/ACompleted

Blood Glucose Response After Oral Intake of Lactulose in Healthy Volunteers

Started Nov 2016
24 enrolled
Blood Glucose
NCT02377947N/ACompleted

A Retrospective, Open-label, Uncontrolled Cohort Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West Haven Criteria) Hepatic Encephalopathy (HE) [The RETRO Study]

Started Dec 2015
50 enrolled
Hepatic Encephalopathy
NCT02228616Phase 4Completed

Efficacy and Safety of Prucalopride in Combination With Polyethylene Glycol or Lactulose in Women With Chronic Constipation

Started Oct 2014
280 enrolled
Constipation
Data Sources
  • Drug label: DailyMed / FDA
  • Clinical trials: ClinicalTrials.gov
  • Patent data: FDA Orange Book
  • Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.